Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“BAXFENDY (baxdrostat) is a new FDA‑approved prescription medicine that lowers blood pressure by directly targeting aldosterone.”
UnverifiableConfidence: LOW

Reasoning

The CBS News video excerpts describe BAXFENDY® (baxdrostat) as a newly FDA‑approved prescription drug used with other antihypertensives to treat high blood pressure in adults, and they specify its mechanism as direct targeting of the hormone aldosterone. This directly corroborates each element of the claim.

On confidence: Both provided excerpts explicitly state that BAXFENDY (baxdrostat) is an FDA‑approved prescription medicine that lowers blood pressure by directly targeting aldosterone.

Important context

The evidence comes from a CBS News segment featuring Dr. Dmitry Yaranov, an AstraZeneca brand partner, and includes a reference to the product's prescribing information.

Evidence

Supporting (2)

Limitations

The sources are promotional (sponsored by AstraZeneca) and not independent regulatory documents; however, they directly quote the FDA‑approval status and mechanism, which is sufficient for verification of the claim as presented. No independent origin corroborated this claim, so it cannot be verified and confidence cannot be high.

Last verified:
Sep 30, 2026, 5:38 PM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

Did you know a hormone could be why blood pressure stays high?